BioLife Solutions Customer Capricor Therapeutics Provides Update on Heart Failure Cell Therapy Safety Data at American Heart Association Scientific Sessions

BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers (“BioLife” or the “Company”), today announced its customer Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, announced positive six-month safety and adverse event data from its ongoing DYNAMIC (Dilated cardiomYopathy iNtervention with Allogeneic MyocardIally-regenerative Cells) clinical trial evaluating CAP-1002 in patients with advanced heart failure. The data were highlighted in a poster presentation on November 9 at the 2015 American Heart Association (AHA) Scientific Sessions in Orlando, FL.
BioLife’s CryoStor cryopreservation media is an integral component in the manufacturing process of CAP-1002 and is used to freeze and administer these therapeutic cells to heart failure patients. CAP-1002 is Capricor’s lead investigational allogeneic, cardiosphere-derived cell (CDC) therapy.
Multi-vessel intracoronary infusion of CAP-1002 in subjects with dilated cardiomyopathy was shown to be safe in this study with no major adverse cardiac events reported at one month or at six months post-infusion. Though this trial was intended as an early safety study, the six-month data demonstrated encouraging and congruent preliminary efficacy signals in multiple parameters, including subjective well being, exercise capacity, ejection fraction and ventricular volumes.
Mike Rice, BioLife’s President & CEO, said, “We are pleased that Capricor used our CryoStor cryopreservation media in its successful DYNAMIC trial. We look forward to the results of the HOPE-Duchenne trial, which has recently opened for enrollment, and also the ALLSTAR Phase II trial. CryoStor is also used in these clinical trials. To date, CryoStor and our HypoThermosol® cell and tissue storage and shipping media are now embedded in over 200 pre-clinical validations and clinical trials of new cell-based products and therapies.”
Source: BioLife Solutions